BeStock  
Stocks › Drug Manufacturers - Specialty & Generic › SUPN

Supernus Pharmaceuticals SUPN

US equityMarket cap rank #2627Drug Manufacturers - Specialty & Generic
$42.76 +$0.38 (+0.90%)
Market closed · Oct 6, 4:30 am ET · Last extended-hours $42.76 0.00%
Open$42.38
Prev close$42.38
Day range$42.38 – $43.20
Volume1.29M
Market cap$2.49B
P/E (TTM)–
Dividend yield–

SUPN Stock News

Headlines matching Supernus Pharmaceuticals or the SUPN ticker, most recent first.

  • Supernus Pharmaceuticals: Supernus Pharmaceuticals, Inc. - Anticipated Adjustment Option Symbol: SUPN New Symbol: SUPN1OCC · 17 Sep 2026
  • TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65Market news · 4 Aug 2026
  • Earnings Flash (SUPN) Supernus Pharmaceuticals Posts Q2 Net Loss $1.01 a Share, Vs. FactSet Est of $0.04 EPSMT Newswires · 3 Aug 2026
  • Earnings Flash (SUPN) Supernus Pharmaceuticals, Inc. Reports Q2 Revenue $219.1M, Vs. FactSet Est of $205.3MMT Newswires · 3 Aug 2026
  • Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $67Market news · 9 Jul 2026
  • Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $66Market news · 27 Jul 2026
  • BofA Securities Initiates Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Announces Target Price $63Market news · 13 Jul 2026
  • Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $55Market news · 7 May 2026
  • Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $66Market news · 13 Apr 2026
  • TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $65Market news · 25 Feb 2026
  • BofA Securities Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65Market news · 25 Feb 2026
  • Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $63Market news · 9 Jan 2026
  • Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $65Market news · 28 Jan 2026
  • Cantor Fitzgerald Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Raises Target Price to $63Market news · 30 Sep 2025
  • Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Raises Target Price to $43Market news · 7 Aug 2025

Discussion

No comments yet — be the first to weigh in on SUPN.

Leave a comment

Scroll to Top